

April 19, 2011



Cryo-Cell Featured in Forbes

Company's Revolutionary Menstrual Stem Cell Technology May Potentially Transform the Stem Cell Industry

OLDSMAR, Fla., April 19, 2011 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTCBB:CCEL) (the "Company"), one of the world's largest and most established family cord blood banks and global industry leader in innovative stem cell solutions, announced today that the Company is featured in a special section entitled Florida: Women in Business of the April 25, 2011 issue of Forbes. A full version of the article which profiles Cryo-Cell International, Inc. and its proprietary menstrual stem cell technology may be found at <http://www.cryo-cell.com/resources/webCryoCell042511FBFL.pdf>.

"Célle has provided an amazing breakout platform for Cryo-Cell as a global leader in stem cell innovation," stated Mercedes A. Walton, Chairman & CEO of Cryo-Cell International. "The Forbes article describes how Cryo-Cell pioneered the private family cord blood banking industry in 1992, and may potentially transform the stem cell industry and future of regenerative medicine with the Company's revolutionary menstrual stem cell technology."

About Cryo-Cell International, Inc.

Based in Oldsmar, Florida, with over 230,000 clients worldwide, Cryo-Cell is one of the largest and most established family cord blood banks. ISO 9001:2008 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. In November 2007, the Company launched CélleSM (pronounced "C-L"), the world's first-ever commercial service allowing women to cryopreserve their own menstrual stem cells. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit www.cryo-cell.com.

About Célle

The CélleSM service was introduced in November 2007 as the first and only service that empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly their first-degree relatives in a manner similar to umbilical cord blood stem cells. For more information, visit www.celle.com.

Forward-Looking Statement

Statements wherein the terms "believes", "intends", "projects", "anticipates", "expects", and similar expressions as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the

Company. These uncertainties and other factors include the success of the Company's global expansion initiatives and product diversification, the Company's actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company's future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company's business, the Company's ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations, the success and enforceability of the Company's C  lle technology license agreements and U-Cord license agreements and their ability to provide the Company with royalty fees, the ability of Cryology RTS to generate new revenues for the Company and those risks and uncertainties contained in risk factors described in documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.

CONTACT: Julia Avery (Investors)
Stern Investor Relations, Inc.
212-362-1200
julia@sternir.com

Irene Smith (Media)
Cryo-Cell International, Inc.
813-749-2100
ismith@cryo-cell.com

Source: Cryo-Cell International, Inc.